⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 3, 2024Journal of Medicinal Chemistry

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

Tianbang Wu Jiankang Hu Xiao‐Fan Zhao Cheng Zhang Ruibo Dong Qingqing Hu Hongrui Xu Hui Shen Xiaohan Zhang Yan Zhang Bin Lin Xishan Wu Qiuping Xiang Yong Xu

View Full Paper

Ask AI

Bookmark

Share

Abstract

The epigenetic target CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) and its homologue p300 were promising therapeutic targets for the treatment of acute myeloid leukemia (AML). Herein, we report the design, synthesis, and evaluation of a class of CBP/p300 PROTAC degraders based on our previously reported highly potent and selective CBP/p300 inhibitor

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2024) studied this question.

synapsesocial.com/papers/68e66608b6db6435875f28f4 https://doi.org/10.1021/acs.jmedchem.4c00335

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong <i>In Vivo</i> Antitumor Activity2024 · 25 citations
2An orally active dual CBP/p300 degrader targets core dependencies of multiple myelomaOriginal Research · 2026
3Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignanciesOriginal Research · 2026 · 2 citations
4Abstract 4484: Characterization and pre-clinical development of LG-CBP/p300 inhibitor, a potent and selective bromodomain inhibitor of CBP/p300.Original Research · 2026
5Abstract 5178: Discovery and characterization of a selective p300 degrader reveals deep anti-tumor activity in CBP mutant cancersOriginal Research · 2026